



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number: 0 603 159 A2

⑫ EUROPEAN PATENT APPLICATION

㉑ Application number: 94102274.1

㉑ Int. Cl. 5: A61K 37/36, A61K 47/26

㉒ Date of filing: 28.03.89

This application was filed on 15 - 02 - 1994 as a divisional application to the application mentioned under INID code 60.

㉓ Priority: 15.04.88 US 182262

㉔ Date of publication of application:
22.06.94 Bulletin 94/25

㉕ Publication number of the earlier application in accordance with Art.76 EPC: 0 409 870

㉖ Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

㉗ Applicant: GENENTECH, INC.
460 Point San Bruno Boulevard

㉘ South San Francisco California 94080(US)

㉙ Inventor: Pearlman, Rodney
PO Box 2108
El Granada, California 94018(US)
Inventor: Oeswein, James C.
PO Box 13
Moss Beach, California 94038(US)

㉚ Representative: Nicholls, Kathryn Margaret et al
MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP (GB)

㉛ Human growth hormone formulation.

㉜ Dimer and aggregate formation in hGH formulations liable to exposure to shear surface stresses is inhibited by the inclusion of 0.1 to 5% w/v of a non-ionic surfactant such as polysorbate 80 or poloxamer 188.




FIG. 8A




FIG. 8B

Field of Invention

5 The present invention is directed to pharmaceutical formulations containing human growth hormone (hGH) and to methods for making and using such formulations. More particularly, this invention relates to such pharmaceutical formulations having increased stability in a lyophilized formulation and upon reconstitution. The formulation is also very stable during processing. Formulations are provided for immediate, safe, effective therapeutic administration to human subjects.

Background of the Invention

10 Human growth hormone (hHG) is secreted in the human pituitary. In its mature form it consists of 191 amino acids, has molecular weight of about 22,000, and thus is more than three times as large as insulin. This hormone is a linear polypeptide containing two intrachain disulfide bridges. Until the advent of recombinant DNA technology, hGH could be obtained only by laborious extraction from a limited source-
15 -the pituitary glands of human cadavers. The consequent scarcity of the substance limited its application to treatment of hypopituitary dwarfism even though it has been proposed to be effective in the treatment of burns, wound healing, dystrophy, bone knitting, diffuse gastric bleeding and pseudarthrosis. hGH can be produced in a recombinant host cell, in quantities which would be adequate to treat hypopituitary dwarfism and the other conditions for which it is effective. See, for example, U.S. Patent 4,342,832.

20 The major biological effect of hGH is to promote growth. The organ systems affected include the skeleton, connective tissue, muscles, and viscera such as liver, intestine, and kidneys. Growth hormone exerts its action through interaction with specific receptors on cell membranes.

Human growth hormone has been formulated in a variety of ways as shown in Table I.

25

30

35

40

45

50

TABLE I

| | hGH (ug/ml upon reconstitution) | hGH (ug/ml upon reconstitution) | Molar Ratio of hGH-1 | Glycine (mg/ml upon reconstitution) | Molar Ratio of hGH-1 | Buffer (mg/ml upon reconstitution) | pH (of reconstituted solution) |
|--|--|--|-------------------------------------|--|-------------------------------------|---|---|
| Genentech Protoprin (5 ug per vial) | 1.0 r-met hGH | 8.0 | (960) | 0 | (0) | 0.83 sodium phosphate | 7.6 |
| Genentech Clinical rhGH formulation (5 ug per vial (NDA)) (2 ug per vial (NDA)) | 1.0 r-hGH | 0 | (0) | 18.9 | (5510) | 1.8 Dibasic sodium phosphate dodecahydrate | 7.4 |
| Lilly met-hGH (2 ug per vial) | 1.0 r-met hGH | 3.5 | (420) | 1.0 | (294) | 0.227 Na ₂ HPO ₄ | 7.2 |
| Lilly r-hGH (2 ug per vial) | 1.0 rhGH | 5.0 | (611) | 1.0 | (294) | 0.227 Na ₂ HPO ₄ | 7.2 |
| KabiVitrum Crescogen (4 I.U. per vial) | 2.0 I.U. pit. hGH | 0 | (0) | 20.0 | (ca. 3860) | 0.5 sodium phosphate | 7.4 |
| Serono Pituitary hGH (2 and 10 I.U. per vial) | 2.0 I.U. pit. hGH | 20.0 | (ca. 2413) | 0 | | 1 sodium phosphate | |

In order that materials like hGH be provided to health care personnel and patients, these materials must be prepared as pharmaceutical compositions. Such compositions must maintain activity for appropriate periods of time, must be acceptable in their own right to easy and rapid administration to humans, and must be readily manufacturable. In many cases pharmaceutical formulations are provided in frozen or in lyophilized form. In this case, the composition must be thawed or reconstituted prior to use. The frozen or

lyophilized form is often used to maintain biochemical integrity and the bioactivity of the medicinal agent contained in the compositions under a wide variety of storage conditions, as it is recognized by those skilled in the art that lyophilized preparations often maintain activity better than their liquid counterparts. Such lyophilized preparations are reconstituted prior to use by the addition of suitable pharmaceutically acceptable diluent(s), such as sterile water for injection or sterile physiological saline solution, and the like.

5 Alternatively, the composition can be provided in liquid form appropriate for immediate use. Desirable is a liquid formulation which maintains its activity in long term storage.

Current formulation of hGH lose activity due to formation of dimer and higher order aggregates (macro range) during formulation processing as well as during storage and reconstitution. Other chemical changes, 10 such as deamidation and oxidation may also occur upon storage.

Prior attempts to stabilize hGH have not fully succeeded in preventing dimer formation. The problems associated with dimer being present are noted in Becker, G.W., Biotechnology and Applied Biochemistry 9, 478 (1987).

EP 303746 discloses formulations containing animal growth hormone, buffer and one or more 15 stabilisers, but there is no specific formulation of human growth hormone.

EP 211601 discloses the use of certain block copolymers in growth hormone formulations. Neither of these references provides any effective teaching for preventing HGH dimer formation.

It is an object of the present invention to prepare stable, aggregate-free formulations of human growth 20 hormone.

A further object of the invention is to provide a formulation which can be aerosolized for pulmonary use, or used in a needleless jet injector for subcutaneous injection.

A further object of the invention is to provide an hGH formulation with enhanced characteristics.

A still further object of the invention is to provide an hGH formulation wherein no component is derived from animals e.g. natural albumin, thus avoiding possible contamination of the formulation with impurities.

25 Other objects, features and characteristics of the present invention will become more apparent upon consideration of the following description and the appended claims.

Summary of the Invention

30 Objects of this invention are accomplished by a pharmaceutically acceptable formulation comprising a pharmaceutically effective amount of human growth hormone, glycine, mannitol, and a buffer, said formulation having an hGH: glycine molar ratio of from 1:50 to 1:200. Advantageously the pH of the formulation is 4-8 adjusted with buffer, and the formulation has a purity level which is pharmaceutically acceptable. In another embodiment, the invention comprises a pharmaceutically effective amount of human 35 growth hormone, glycine, mannitol, a buffer and a non-ionic surfactant, wherein said formulation is capable of undergoing processing and storage with substantially no dimer formation. The invention also comprises a method of stabilizing a formulation of human growth hormone comprising the steps of combining human growth hormone with glycine, mannitol and a buffer to make a pharmaceutically acceptable formulation, and wherein the molar ratio of human growth hormone:glycine is 1:50-200. The invention also includes a method 40 of administering human growth hormone with an aerosol device or needleless injector gun, wherein the formulation comprises human growth hormone, mannitol, glycine, a buffer, and a non-ionic surfactant.

Description of the Figures

45 Figure 1 is a plot of the first order rate constants for deamidation of hGH in solution, vs. pH. The rate constants were determined by incubating hGH samples prepared at various pH values, at either 25 °C or 40 °C, and measuring the amount of deamidation occurring as a function of time by quantitative isoelectric focusing (IEF) gel electrophoresis. Thus the lower the pH, the less deamidation occurs, with a minimum at about pH 6.0. A similar dependency occurs in the solid state, with much slower reaction rates.

50 Figure 2 is a plot of the logarithm of the number of 2 µm particles (as detected by a HIAC-Royco particle analyzer) vs. pH for solutions of hGH before lyophilization. This figure shows that as the pH decreases from 8 to 6, the mount of aggregation, as measured by the number of particles, increases.

55 Figure 3 shows three chromatograms of reverse phase HPLC, from three hGH samples buffered at pH values 6.0, 6.5 and 7.2, and stored for 47 days at 40 °C in the lyophilized state. They show that as the pH is decreased (toward 6.0) a greater amount of "trailing peak" is formed.

Figure 4 is a plot of the percent trailing band vs. pH, upon storage at either 40 °C or 60 °C for samples made at various pH values, and lyophilized. This graph shows in a quantitative form, that lower pH values produce more trailing band upon storage.

Figure 5 describes the amount of UV light absorbed (or scattered) vs. wavelength for hGH made upon with three different concentrations of buffer, all at pH 7.4. The plots show that more scatter (i.e. aggregation) is present in samples at buffer concentrations lower than 5mM.

Figure 6 is a plot of % dimer formed in lyophilized samples of hGH vs. time, upon storage at 40 °C.

5 The samples comprised of hGH prepared in mannitol alone (MANNITOL) with a molar ratio hGH:mannitol 1:1100, or glycine alone (GLYCINE) with a glycine molar ration hGH:glycine 1:5540, or with a mixture of hGH:glycine:mannitol in a molar ratio of 1:100:1100 (100GLY). all samples had the same amount of sodium phosphate buffer (5 mM at pH 7.4).

Figure 7 is a plot of % dimer formed in lyophilized samples of hGH vs. time, upon storage at 40 °C.

10 The samples comprised of hGH prepared in varying mixtures of mannitol and glycine, with the same amount (5 mM) of sodium phosphate buffer at pH 7.4. The code for the various molar ratios of hGH:glycine:mannitol are 1:10:1100 (10GLY), 1:100:1100 (100GLY) and 1:1000:1100 (100GLY).

15 Figure 8A is a size exclusion chromatogram of growth hormone after nebulization from a standard aerosol nebulizer (Turret Brand™). The chromatogram shows that only about 33% of the growth hormone is present as intact monomer, the remainder being dimer, trimer and higher order aggregates. These results were confirmed by native polyacrylamide gel electrophoresis. Figure 8B is the size exclusion chromatogram of growth hormone after nebulization, in the same formulation as the figure above with the inclusion of polysorbate 80, 1%. This figure shows the lack of any aggregation occurring. Similar results were also obtained when poloxamer 188, 1% was used instead of polysorbate 80.

20 (Poloxamer and Polysorbate are trade marks).

Detailed Description of the Invention

The present invention is based upon the discovery that the inclusion of glycine and mannitol in a 25 specific pharmaceutically acceptable formulation of human growth hormone maintains the activity of hGH, and inhibits undesirable reactions that hGH undergoes during processing, reconstitution, and storage. As used herein, the term processing includes filtration, filling into vials and lyophilization. In a preferred embodiment, a non-ionic surfactant such as polysorbate 80 is added for reduced aggregation and denaturation. The invention is thus directed to such formulations, and to all associated formulations and to 30 means for effectively stabilizing human growth hormone.

As used herein, the terms "human growth hormone" or "hGH" denote human growth hormone produced, for example, from natural source extraction and purification, and by recombinant cell culture systems. Its sequence and characteristics are set forth, for example, in Hormone Drugs, Gueriguian et al., U.S.P. Convention, Rockville, MD (1982). The terms likewise cover biologically active human growth 35 hormone equivalents; e.g., differing in one or more amino acid(s) in the overall sequence. Further, the terms as used in this application are intended to cover substitution, deletion and insertion amino acid variants of hGH, or post translational modifications. Human growth hormone is generally produced by recombinant means.

The formulation of the subject invention comprises:

40 a) hGH
b) Glycine
c) Mannitol
d) Buffer

wherein the molar ratio of hGH:glycine is 1:50-200, advantageously 1:75-125, and the molar ratio of 45 hGH:mannitol is 1:700-3000, advantageously 1:800-1500. In a preferred embodiment the buffer is a phosphate buffer and the molar ratio of hGH:phosphate buffer is 1:50-250, advantageously 1:75-150. In another embodiment a non-ionic surfactant is added to the formulation. Advantageously polysorbate 80 is used, and the molar ratio of hGH:polysorbate 80 is 1:0.07-30, advantageously 1:0.1-10.

In a preferred embodiment, the formulation of the subject invention comprises the following components 50 at pH 7.4:

| Ingredient | Quantity per ml upon reconstitution (mg) | Molar Ratio |
|---|--|-------------|
| r-hGH | 1.0 | 1 |
| Glycine | 0.34 | 100 |
| Mannitol | 9.0 | 1100 |
| NaH ₂ PO ₄ • H ₂ O | 0.18 | |
| NaH ₂ PO ₄ • 12H ₂ O | 1.32 | 110 |
| Polysorbate 80 | 0.20 | 3 |

5

In general, the formulations of the subject invention may contain other components in amounts preferably not detracting from the preparation of stable forms and in amounts suitable for effective, safe pharmaceutical administration.

10 Suitable pH ranges, adjusted with buffer, for the preparation of the formulations hereof are from 4 to 8, advantageously 5 to 8, most advantageously 7.4. The formulation pH should be less than 7.5 to reduce deamidation (see Figure 1). pH values below 7.0 result in particulate formation upon lyophilization (see Figure 2). The aggregation is not related to deamidation.

15 Storage of lyophilized r-hGH at 40 and 60 °C resulted in increased formation of a trailing peak by HPLC. This peak increased with lower pH values (see Figures 3 and 4). Consequently pH 7.4 is an advantageous pH.

20 The molar ration of hGH:glycine is 1:50-200, advantageously 1:75-125, most advantageously 1:100. Glycine greatly inhibits dimer formation when it is added in these ratios. Ratios of 1:10 and 1:1000 result in substantial dimer formation upon lyophilization. Glycine, which is a nonessential amino acid, has the formula 25 NH₂CH₂ COOH. In addition to glycine, an amino acid such as alanine or derivatives of such amino acids are used in the subject formulation.

25 The molar ratio of hGH:mannitol is 1:700-2000, advantageously 1:800-1500, and most advantageously 1:1100. A formulation containing mannitol as the sole bulking agent, results in greater aggregate and dimer formation than one containing a mixture of mannitol and glycine. As an alternative to mannitol, other sugars or sugar alcohols are used such as sucrose, maltose, fructose, lactose and the like.

30 The preferred buffer is a phosphate buffer and the molar ratio of hGH:phosphate buffer is 1:50-250, advantageously 1:75-150, most advantageously 1:110. A buffer concentration greater than or equal to 2.5mM and less than 20mM is preferred, most advantageously 5-10mM (see Figure 5). In this concentration range of buffer, minimal aggregation occurs. Advantageously a sodium phosphate or tris buffer is used.

35 The effect of using a mannitol-glycine mixture as the lyophilization bulking matrix is compared with using either mannitol alone, or glycine alone in Figures 6 and 7. All samples were buffered with 5 mM sodium phosphate buffer, pH 7.4. These figures are plots of the influence of bulking matrix on the formation of dimer over time, at a storage temperature of 40 °C.

40 Figure 6 demonstrates that a molar ratio of hGH:glycine:mannitol of 1:100:1100 results in the formation of less dimer upon storage, than either mannitol alone or glycine alone.

45 The importance of the molar ratio of hGH to glycine is shown in Figure 7, wherein the hGH:mannitol molar ratio is fixed at 1:1100, and the hGH:glycine molar ratio is varied from 1:10, 1:100, 1:1000. The least amount of dimer forms in the sample which has an hGH:glycine molar ratio of 1:100. More dimer is formed in the other two cases.

50 The formulation of the subject invention may optionally include one of several types of non-ionic surfactants, such as the polysorbates (e.g. polysorbate 20,80, etc.) and the poloxamers (e.g. poloxamer 188). When polysorbate 80 is used the molar ratio of hGH:polysorbate 80 is 1:0.07-30, advantageously 1:0.1-10, and most advantageously 1:3. On a weight to volume basis, polysorbate 80 is added in amount of about 0.001 to about 2% (w/v), in order to enhance further the stability of the hGH. Polysorbate 80, in concentrations above 0.01% (w/v) reduces the amount of aggregation forming upon lyophilization. In addition to improved shelf life, the surfactant containing formulation of the subject invention inhibits the formation of protein aggregates when the reconstituted formulation is shaken.

55 Other pharmaceutically acceptable excipients well known to those skilled in the art may also form a part of the subject compositions. These include, for example, various bulking agents, additional buffering agents, chelating agents, antioxidants, preservatives, cosolvents, and the like; specific examples of these could include, trimethylamine salts ("Tris buffer"), and disodium edetate. In one embodiment, no proteins other than hGH are part of the formulation.

60 In a further embodiment of this invention, the use of nonionic surfactants permits the formulation to be exposed to shear surface stresses without causing denaturation of the protein. Further, such surfactant

containing formulations, may be employed in aerosol devices such as those used in a pulmonary dosing, and needless jet injector guns.

In order to prevent surface induced denaturation of hGH that occurs during aerosolization of an hGH formulation concentrations of non-ionic surfactants in the range 0.1 - 5% (w/v) are used. Figure 8A shows the 5 severe aggregation of hGH in a mannitol/phosphate buffer upon aerosolization. Only about 30% of the protein is present as intact monomer. The remainder has formed dimer, trimer and higher order aggregates. The formation of aggregates was eliminated as shown in Figure 8B which was obtained from a sample after aerosolization of the hGH in a mannitol phosphate buffer, containing 1% polysorbate 80.

A "pharmaceutically effective amount" of hGH refers to that amount which provides therapeutic effect in 10 various administration regimens. The compositions hereof may be prepared containing amounts of hGH at least about 0.1 mg/ml, upwards of about 10 mg/ml, preferably from about 1 mg/ml to about 5 mg/ml. For use of these compositions in administration to human patients suffering from hypopituitary dwarfism, for example, these compositions may contain from about 0.1 mg/ml to about 10 mg/ml, corresponding to the currently contemplated dosage rate for such treatment.

15 The formulations are prepared in general by combining the components using generally available pharmaceutical combining techniques, known per se. A particular method for preparing a pharmaceutical formulation of hGH hereof comprises employing hGH purified according to any standard protein purification scheme.

20 EXPERIMENTAL

A. Formulation preparation

A solution of protein in the final formulation is prepared by buffer exchange on a gel filtration column. 25 The elution buffer contains glycine, mannitol, buffer and the non-ionic surfactant in their final ratios. The concentration of the protein is obtained by dilution of this resulting solution to a desired protein concentration.

The solution is sterile filtered, and can be stored for several weeks at 5 °C, or, filled into sterile vials and 30 freeze-dried using an appropriate lyophilization cycle.

B. Analytical Methods

Quantitative isoelectric focusing gel electrophoresis was used to determine the rate of deamidation of hGH, by measurement of the acidic material forming with time.

35 Reversed phase high performance liquid chromatography (RPHPLC) was used to follow the degradation profile of hGH with time. The method employed a C4RP column (4.5 mm ID x 25 cm) and a mobile phase composed of 60:40 water, containing 0.1% trifluoroacetic acid: acetonitrile, containing 0.1% trifluoroacetic acid which was ramped to 30:70 water:acetonitrile at 1% per minute. Detection was made by UV absorbance.

40 Gel permeation chromatography (GPC) was employed to separate and quantitate dimer and higher order aggregates from monomeric hGH. It comprised a Superose 12^R column and elution was effected with a pH 7 buffer containing 150 mM sodium chloride. Detection was performed by UV absorbance.

HIAC-Royco particle size analysis was used to measure particle size and distribution of reconstituted 45 solutions of hGH by means of a light blockage technique.

UV scans were used to measure both the concentration of the protein, and absorbance due to scatter (i.e. aggregation).

Claims

- 50 1. A composition in liquid form comprising hGH and 0.1 to 5% (w/v) of a non-ionic surfactant.
2. A composition according to claim 1 further comprising mannitol.
3. A composition according to claim 1 wherein the non-ionic surfactant is polysorbate 20^R or poloxamer 55 188^R.
4. A composition according to claim 3 wherein the non-ionic surfactant is polysorbate 20^R.

EP 0 603 159 A2

5. A composition according to claim 3 wherein the non-ionic surfactant is poloxamer 188^R at a level of 1% (w/v).
6. A composition according to any one of the preceding claims comprising 0.1 to 10 mg/ml hGH.

5

10

15

20

25

30

35

40

45

50

55

FIG. 1




FIG. 2





FIG. 3






FIG. 4

FIG. 5




FIG. 6





FIG. 7



EP 0 603 159 A2




FIG. 8A




FIG. 8B



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number:

0 603 159 A3

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 94102274.1

⑮ Int. Cl. 6: **A61K 38/27, A61K 47/10,
A61K 47/26**

⑯ Date of filing: 28.03.89

⑭ Priority: 15.04.88 US 182262

⑰ Applicant: GENENTECH, INC.
460 Point San Bruno Boulevard
South San Francisco
California 94080 (US)

⑮ Date of publication of application:
22.06.94 Bulletin 94/25

⑯ Inventor: Pearlman, Rodney
PO Box 2108
El Granada, California 94018 (US)
Inventor: Oesweln, James C.
PO Box 13
Moss Beach, California 94038 (US)

⑯ Publication number of the earlier application in
accordance with Art.76 EPC: 0 409 870

⑰ Representative: Nicholls, Kathryn Margaret et
al
MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP (GB)

⑯ Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

⑯ Date of deferred publication of the search report:
13.12.95 Bulletin 95/50

⑯ Human growth hormone formulation

⑯ Dimer and aggregate formation in hGH formulations liable to exposure to shear surface stresses is inhibited by the inclusion of 0.1 to 5% w/v of a non-

ionic surfactant such as polysorbate 80 or poloxamer 188.




FIG. 8A




FIG. 8B



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 94 10 2274

| DOCUMENTS CONSIDERED TO BE RELEVANT | | | | | | | | | |
|--|--|-------------------|---|---|--|----------|-----------|-----------------|--------------|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int.Cl.) | | | | | | |
| D, Y | EP-A-0 211 601 (INTERNATIONAL MINERALS AND CHEMICAL CORPORATION) * claims * * page 4, line 4 - line 7 * * page 5, line 9 - page 6, line 3 * * page 9, line 2 - line 5 * --- | 1-6 | A61K38/27 A61K47/10 A61K47/26 | | | | | | |
| Y | EP-A-0 193 917 (AMERICAN CYANAMID COMPANY) * claims 1,2,5,6,8 * * page 4, line 26 - line 27 * * examples 4,7,8 * --- | 1-6 | | | | | | | |
| D, P, Y | EP-A-0 303 746 (INTERNATIONAL MINERALS AND CHEMICAL CORPORATION) * claims 1,2,8,10-12 * * page 4, line 1 * * tables 1,2 * ----- | 1-6 | | | | | | | |
| | | | TECHNICAL FIELDS SEARCHED (Int.Cl.) | | | | | | |
| | | | A61K | | | | | | |
| <p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>19 October 1995</td> <td>Scarpioni, U</td> </tr> </table> | | | | Place of search | Date of completion of the search | Examiner | THE HAGUE | 19 October 1995 | Scarpioni, U |
| Place of search | Date of completion of the search | Examiner | | | | | | | |
| THE HAGUE | 19 October 1995 | Scarpioni, U | | | | | | | |
| <p>CATEGORY OF CITED DOCUMENTS</p> <table border="0" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top;"> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document </td> <td style="width: 50%; vertical-align: top;"> T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document </td> </tr> </table> | | | | X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document | T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document | | | | |
| X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document | T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document | | | | | | | | |